Management of myocardial infarction in children with Kawasaki disease

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 7, 2010, Pages 620-631

  Paredes, Nethnapha ^a   Mondal, Tapas ^b   Brandão, Leonardo R ^c   Chan, Anthony K C ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

children; Kawasaki disease; myocardial infarction; thrombolytic therapy

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA THROMBOGLOBULIN; CAPTOPRIL; CLOPIDOGREL; DIGOXIN; DIPYRIDAMOLE; DOPAMINE; FLURBIPROFEN; GLYCERYL TRINITRATE; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ANEURYSM; AORTA VALVE REGURGITATION; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY ANEURYSM; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY THROMBOSIS; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDITIS; PERICARDITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; THROMBOCYTOSIS; THROMBOSIS; TREATMENT OUTCOME;

CHILD; DISEASE MANAGEMENT; HUMANS; INFANT, NEWBORN; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 77958175887     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32833d6ec2     Document Type: Review

References (79)

1. Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986; 108:923-927. (Pubitemid 16096813)
2. Kato H, Ichinose E, Yoshioka F, Takechi T, Matsunaga S, Suzuki K, Rikitake N. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol 1982; 49:1758-1766. (Pubitemid 12003490)
3. Suzuki A, Kamiya T, Kuwahara N, Ono Y, Kohata T, Takahasi O, et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 1986; 7:3-9. (Pubitemid 17203428)
4. Akagi T, Rose V, Benson LN, Newman A, Freedom RM. Outcome of coronary artery aneurysms after Kawasaki disease. J Pediatr 1992; 121 (5 Pt 1):689-694.
5. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324:1633-1639.
6. Takahashi M, Mason W, Lewis AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 1987; 75:387-394. (Pubitemid 17007345)
7. Levy DM, Silverman ED, Massicotte MP, McCrindle BW, Yeung RS. Longterm outcomes in patients with giant aneurysms secondary to Kawasaki disease. J Rheumatol 2005; 32:928-934.
8. Nakano H, Ueda K, Saito A, Nojima K. Repeated quantitative angiograms in coronary arterial aneurysm in Kawasaki disease. Am J Cardiol 1985; 56:846-851. (Pubitemid 16206951)
9. Tatara K, Kusakawa S. Long-term prognosis of giant coronary aneurysm in Kawasaki disease: an angiographic study. J Pediatr 1987; 111:705-710. (Pubitemid 18017898)
10. Nakano H, Saito A, Ueda K, Nojima K. Clinical characteristics of myocardial infarction following Kawasaki disease: report of 11 cases. J Pediatr 1986; 108:198-203. (Pubitemid 16124805)
11. Gersony WM. Diagnosis and management of Kawasaki disease. JAMA 1991; 265:2699-2703.
12. Newburger JW, Takahashi M, Gerber M, Gewitz MH, Tani LY, Burns JC, et al. Committee on Rheumatic Fever EaKD. Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. [Erratum in Pediatrics. 2005 Apr;115(4):1118]. Pediatrics 2004; 144:1708-1733. (Pubitemid 41754943)
13. Bor I. Myocardial infarction and ischaemic heart disease in infants and children. Analysis of 29 cases and review of the literature. Arch Dis Child 1969; 44:268-281.
14. Yanagisawa M, Kobayashi N, Matsuya S. Myocardial infarction due to coronary thromboarteritis, following acute febrile mucocutaneous lymph node syndrome (MLNS) in an infant. Pediatrics 1974; 54:277-280.
15. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978; 61:100-107. (Pubitemid 8268802)
16. Hicks R, Melish M. Kawasaki syndrome. Pediatr Clin North Am 1986; 33:1151-1157. (Pubitemid 16009059)
17. Bierman FZ, Gersony WM. Kawasaki disease: clinical perspective. J Pediatr 1987; 111:789-793.
18. Radford DJ, Sondheimer HM, Williams GJ, Fowler RS. Mucocutaneous lymph node syndrome with coronary artery aneurysm. Am J Dis Child 1976; 130:596-598. (Pubitemid 8000902)
19. Kegel SM, Dorsey TJ, Rowen M, Taylor WF. Cardiac death in mucocutaneous lymph node syndrome. Am J Cardiol 1977; 40:282-286. (Pubitemid 8159524)
20. Nakagawa M, Watanabe N, Okuno M, Okamoto N, Fujino H. Effects of intracoronary tissue-type plasminogen activator treatment in Kawasaki disease and acute myocardial infarction. Cardiology 2000; 94:52-57.
21. Tsuda E, Arakaki Y, Shimizu H, Sakaguchi H, Yoshimura S, Yazaki S, Echigo S. Changes in causes of sudden deaths by decade in patients with coronary arterial lesions due to Kawasaki disease. Cardiol Young 2005; 15:481-488. (Pubitemid 41630836)
22. Burns JC, Glode MP, Clarke SH, Wiggins J Jr, Hathaway WE. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms. J Pediatr 1984; 105:206-211.
23. Sakai M, Asayama K, Otabe T, Kohri T, Shirahata A. Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease. Clin Appl Thromb Hemost 2001; 7:214-218. (Pubitemid 32574183)
24. Albisetti M, Chan AK, McCrindle BW, Wong D, Vegh P, Adams M, et al. Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease. Blood Coagul Fibrinolysis 2003; 14:181-186. (Pubitemid 36332481)
25. Hidaka T, Nakano H, Ueta T, Komatsu Y, Yamamoto M. Increased synthesis of thromboxane A2 by platelets from patients with Kawasaki disease. J Pediatr 1983; 102:94-96. (Pubitemid 13167862)
26. Niboshi A, Hamaoka K, Sakata K, Yamaguchi N. Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr 2008; 167:189-196.
27. Freeman AF, Shulman ST. Kawasaki disease: summary of the American Heart Association guidelines. Am Fam Physician 2006; 74:1141-1148.
28. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al., Committee on Rheumatic Fever EaKD, American Heart Association, American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747-2771. (Pubitemid 39453026)
29. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003; CD004000.
30. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96:1057-1061.
31. Tsubata S, Ichida F, Hamamichi Y, Miyazaki A, Hashimoto I, Okada T. Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease. Pediatr Cardiol 1995; 16:186-189.
32. Kato H, Inoue O, Ichinose E, Akagi T, Sato N. Intracoronary urokinase in Kawasaki disease: treatment and prevention of myocardial infarction. Acta Paediatr Jpn 1991; 33:27-35.
33. Suzuki A, Tetsuro K, Ono Y, Kinoshita Y. Thrombolysis in the treatment of patients with Kawasaki disease. Cardiol Young 1993; 3:207-215.
34. Terai M, Ogata M, Sugimoto K, Nagai Y, Toba T, Tamai K, et al. Coronary arterial thrombi in Kawasaki disease. J Pediatr 1985; 106:76-78. (Pubitemid 15189914)
35. Monagle P, Chalmers E, Chan A, deVeber G, Kirkham F, Massicotte P, Michelson AD. American College of Chest Physicians. Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed.). Chest 2008; 133 (6 Suppl):887S-968S. (Pubitemid 351892979)
36. Williams RV, Tcheng WY, Minich LL. Anticoagulation in the acute and longterms management of Kawasaki disease. Prog Pediatr Cardiol 2004; 19:179-188. (Pubitemid 39485656)
37. Nakamura Y, Yanagawa H, Kawasaki T. Mortality among children with Kawasaki disease in Japan. N Engl J Med 1992; 326:1246-1249.
38. Burtt DM, Pollack P, Bianco JA. Intravenous streptokinase in an infant with Kawasaki's disease complicated by acute myocardial infarction. Pediatr Cardiol 1986; 6:307-311. (Pubitemid 16003396)
39. Ellis K, Brener S. New fibrinolytic agents for MI: as effective as current agents, but easier to administer. Clev Clin J Med 2004; 71:20-37. (Pubitemid 39220366)
40. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311-322. (Pubitemid 124000789)
41. Katayama F, Hiraishi S, Takeda N, Misawa H. Intracoronary urokinase and postthrombolytic regimen in an infant with Kawasaki disease and acute myocardial infarction. Heart 1997; 78:621-622. (Pubitemid 28034219)
42. Liang CD, Huang SC, Su WJ, Chen HY, Lee CH. Successful intravenous streptokinase treatment of a child with Kawasaki disease complicated by acute myocardial infarction. Cathet Cardiovasc Diagn 1995; 35:139-145.
43. Horigome H, Sekijima T, Miyamoto T. Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki disease. Heart 1997; 78:517-518. (Pubitemid 27515118)
44. Rentrop P, Blanke H, Karsch KR, Kaiser H, Kö stering H, Leitz K. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 1981; 63:307-317. (Pubitemid 11168747)
45. Mathey DG, Kuck KH, Tilsner V, Krebber HJ, Bleifeld W. Non surgical coronary artery recanalization in acute transmural myocardial infarction. Circulation 1981; 63:489-497. (Pubitemid 11139855)
46. Ganz W, Buchbinder N, Marcus H, Mondkar A, Maddahi J, Charuzi Y, et al. Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J 1981; 101:4-13. (Pubitemid 11213429)
47. Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984; 310:609-613. (Pubitemid 14194374)
48. Cheatham JP, Kugler JD, Gumbiner CH, Latson LA, Hofschire PJ. Intracoronary streptokinase in Kawasaki disease: acute and late thrombolysis. Prog Clin Biol Res 1987; 250:517-518.
49. Krendel S, Pollack P, Hanly J. Tissue plasminogen activator in pediatric myocardial infarction. Ann Emerg Med 2000; 35:502-505. (Pubitemid 30643544)
50. GUSSI Study Group. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397-402.
51. The I.S.A.M. Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314:1465-1471. (Pubitemid 16114661)
52. White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317:850-855. (Pubitemid 17156728)
53. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349-360.
54. Dakik HA, Nasrallah A. Repeated doses of tissue plasminogen activator for failed thrombolysis: case report and review of the literature. Heart Dis 2001; 3:362-364. (Pubitemid 34003376)
55. European Cooperative Study Group. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985; 1:842-847.
56. ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2:525-530.
57. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142-154. (Pubitemid 17093202)
58. Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed MD, Ferrieri P, et al. Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994; 89:916-922. (Pubitemid 24979853)
59. Gupta AA, Leaker M, Andrew M, Massicotte P, Liu L, Benson LN, McCrindle BW. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatr 2001; 139:682-688. (Pubitemid 33097434)
60. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97:1680-1688. (Pubitemid 28211416)
61. Ibbotson T, McGavin JK, Goa KL. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs 2003; 63:1121-1163. (Pubitemid 36700391)
62. Investigators EPILOG. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336:1689-1696.
63. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104:163-167.
64. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998; 98:1085-1091.
65. Wu CH, Chen YC, Hsiao G, Lin CH, Liu CM, Sheu JR. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. Thromb Res 2001; 101: 127-138. (Pubitemid 32176018)
66. Chandwaney RH, Stathopoulos T, Sunew J, McPherson D, Davidson CJ. Adjunctive therapies in the cath lab. Successful thrombolysis using the combination of tissue plasminogen activator and abciximab in an adult with Kawasaki's disease. J Invasive Cardiol 2001; 13:651-653. (Pubitemid 33759188)
67. Etheridge SP, Tani LY, Minich LL, Revenaugh JR. Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease. Cathet Cardiovasc Diagn 1998; 45:264-268.
68. Williams RV, Wilke VM, Tani LY, Minich LL. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002; 109:E4.
69. Kitamura S. The role of coronary bypass operation on children with Kawasaki disease. Coron Artery Dis 2002; 13:437-447. (Pubitemid 36132608)
70. Kitamura S, Tsuda E, Kobayashi J, Nakajima H, Yoshikawa Y, Yagihara T, Kada A. Twenty-five-year outcome of pediatric coronary artery bypass surgery for Kawasaki disease. Circulation 2009; 120:60-68.
71. Wakisaka Y, Tsuda E, Yamada O, Yagihara T, Kitamura S. Long-term results of saphenous vein graft for coronary stenosis caused by Kawasaki disease. Circ J 2009; 73:73-77.
72. Yoshikawa Y, Yagihara T, Kameda Y, Taniguchi S, Tsuda E, Kawahira Y, et al. Result of surgical treatments in patients with coronary-arterial obstructive disease after Kawasaki disease. Eur J Cardiothorac Surg 2000; 17:515-519. (Pubitemid 30256259)
73. Mok GC, Sung RY, Yam MC, Arifi AA, Lam WW, Fok TF. A child with Kawasaki disease who survived after rupture of a coronary artery aneurysm. Eur J Pediatr 2003; 162:634-636. (Pubitemid 37100628)
74. Antman EM, Hand M, ArmstrongPW, Bates ER, Green LA, Halasyamani LK, et al. 2004 Writing Committee. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/ AmericanHeart Association Task Force on PracticeGuidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117:296-329.
75. Barton M, Melbourne R, Morais P, Christie C. Kawasaki syndrome associated with group A streptococcal and Epstein-Barr virus coinfections. Ann Trop Paediatr 2002; 22:257-260.
76. Kohr RM. Progressive asymptomatic coronary artery disease as a late fatal sequela of Kawasaki disease. J Pediatr 1986; 108:256-259.
77. Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwettr M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996; 28:253-257. (Pubitemid 26266648)
78. Shaukat N, Ashraf S, Mebewu A, Freemont A, Keenan D. Myocardial infarction in a young adult due to Kawasaki disease. A case report and review of the late cardiological sequelae of Kawasaki disease. Int J Cardiol 1993; 39:222-226. (Pubitemid 23172209)
79. Kato H, Inoue O, Kawasaki T, Fujiwara H, Watanabe M, Toshima H. Adult coronary artery disease probably due to childhood Kawasaki disease. Lancet 1992; 340:1127-1129.